Semafor85%
Eli Lilly makes $3.8 billion bet on psychedelic drugs 100%
By Tom Chivers87%
7/17/2026, 12:54:10 PM
BS Summary: This article contains 17 faulty reasoning types, including Availability Heuristic, Framing Effect, and Ambiguity (Equivocation), with Biased Writer Voice as the most egregious example at 73.6% saturation with 89 hits. Analysis detected 676 faulty-reasoning hits from 121 analyzed words, generating a BS Score of 100% and a BS Rank of 100% (10 of 21,170 articles). This article is worse (more manipulative) than 100.00% of the article peer group.
Eli Lilly will buy a psychedelic drug developer for up to $3.8 billion, a sign of rising interest in using the chemicals as psychiatric treatments.
AtaiBeckley’s BPL-003 psychedelic nasal spray is in late-stage trials to test its effectiveness against treatment-resistant depression; analysts estimate that if it succeeds, it could generate annual sales of up to $1-$2 billion.
The theory is that psychedelic drugs relax strongly held but inappropriate negative beliefs and, in combination with therapy, allow patients to form truer ones.
But testing that theory is difficult — placebo-blinded trials are tricky to do when the real drug makes patients hallucinate — and the industry has faced scandals where therapists abused subjects.
Speakers
Loading…
Loading…
Loading…
Analysis
Hover over highlighted words in the article to view the associated bias or fallacy analysis.